Plasma pharmacokinetics and tissue distribution study of physalin D in rats by ultra-pressure liquid chromatography with tandem mass spectrometry

Wu, Yongjiang; Zheng, Yang; Chen, Na; Luan, Lianjun; Liu, Xuesong

doi:10.1016/j.jchromb.2010.12.032

Cited by 12 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, it showed strong antitumor , antimycobacterial , immune depression , cytotoxic and antimicrobial activities. Our previous study also showed that physalin D has a very short t 1/2 (∼19.8 ± 9.2 min) . However, we did not determine whether rapid metabolic conversion, preferential accumulation in and excretion by the kidney, or both were responsible for its rapid elimination.…”

Section: Introductionmentioning

confidence: 65%

“…The excretion data of physalin D in urine and feces indicated that <14.0% (1.23 and 12.26%, respectively) of the administered dose was excreted in an unconverted form. The results indicated that physalin D was extensively and rapidly metabolized in rats after oral administration, which may be the main factors leading to the short t 1/2 of physalin D .…”

Section: Resultsmentioning

confidence: 95%

“…Several studies have focused on detecting physalin D and its homologues in different matrices using HPLC with UV or MS detection [7,15,17,18]. However, to the best of our knowledge, no analytical method has been developed for detecting physalin D in rat urine and feces.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Identification and quantitative analysis of physalin D and its metabolites in rat urine and feces by liquid chromatography with triple quadrupole time‐of‐flight mass spectrometry

Zheng

Cao

Lin

et al. 2017

J of Separation Science

Self Cite

View full text Add to dashboard Cite

Physalin D is known to show extensive bioactivities. However, no excretion study has elucidated the excretion of physalin D and its metabolites. This study investigates the excretion of physalin D and its metabolites in rats. Metabolites in rat urine and feces were separated and identified by liquid chromatography with triple quadrupole time-of-flight mass spectrometry. Furthermore, a validated high-performance liquid chromatography with tandem mass spectrometry method was developed to quantify physalin D, physalin D glucuronide, and physalin D sulfate in rat feces and urine after the intragastric administration of physalin D. The analyte showed good linearity over a wide concentration range (r > 0.995), and the lower limit of quantification was 0.0532 μg/mL and 0.226 μg/g for urine and feces, respectively. Nine metabolites, including five phase I and four phase II metabolites, were identified and clarified after dosing in vivo. Only 4.0% of the gavaged dose, including physalin D and its phase II metabolites, was excreted in urine, whereas 10.8% was found in feces in the unchanged form. The results indicate that the extensive and rapid metabolism may be the main factors leading to the short half-life of physalin D. These results can provide a basis for further studies on the structural modification and pharmacology of physalin D.

show abstract

Section: Introductionmentioning

confidence: 65%

Section: Resultsmentioning

confidence: 95%

See 1 more Smart Citation

Identification and quantitative analysis of physalin D and its metabolites in rat urine and feces by liquid chromatography with triple quadrupole time‐of‐flight mass spectrometry

Zheng

Cao

Lin

et al. 2017

J of Separation Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a good drug candidate, several methods have been developed to prepare physalin B, including purification from plants (Liu and Wan, ) and synthesis through an organic method (Ohkubo et al , ; Morita et al , ). Our previous studies have showed the pharmacokinetics properties of physalin D, physalin G and 4,7‐didehydroneophysalin B (Wu et al , ; Zheng et al , ); however, there has been no research on the pharmacokinetics and tissue distribution of physalin B. Therefore, it is necessary to develop an effective method to investigate the pharmacokinetic properties of physalin B for a better understanding of the mechanism of its action.…”

Section: Introductionmentioning

confidence: 99%

In vivo pharmacokinetics of and tissue distribution study of physalin B after intravenous administration in rats by liquid chromatography with tandem mass spectrometry

Zheng

Chen

Liu

et al. 2016

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

A rapid and sensitive liquid chromatography tandem mass spectrometry quantitative analysis method was established for the pharmacokinetics and tissue distribution study of physalin B in rat. Physalin B and physalin H (internal standard, IS) were separated on an Agilent Eclips XDB C8 column. MS detection was performed on a triple quadrupole tandem mass spectrometer in the multiple reaction monitoring mode with a positive eletrospray ionization source. The assay was validated in the concentration ranges of 22.6-22600 ng/mL for heart and lung and 4.52-4520 ng/mL for other tissues. The intra- and inter-day precisions (RSD) were ≤9.23 and ≤12.51%, respectively, with accuracy (%) in the range of 88.07-113.2%. A pharmacokinetic study showed that physalin B has a long dwell time with a half-life of 321.2 ± 29.5 min and clearance of 175.4 ± 25.7 mL/min/kg after intravenous administration. Additionally, physalin B showed a wide tissue distribution with a special higher penetration in lung. The data presented in this study could provide useful information for the further study of physalin B. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

“…It was reported as a powerful natural PAF antagonist like ginkgolide B [13], and also had obvious central nervous system protect effects through inhibiting the release of beta-glucuronidase and inhibiting reactive oxygen species generation and Ca 2+ influx [19,20]. It is well acknowledged that pharmacokinetics plays an important role throughout the whole pipeline of new drug discovery [21][22][23][24]. In order to promote the study of GK as a candidate for treating cerebral ischemia, it is imperative to investigate the systemic tissue exposure and plasma pharmacokinetic of GK in vivo.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry

Fan

Liu

Guo

et al. 2015

Journal of Chromatography B

View full text Add to dashboard Cite

Ginkgolide K (GK), a derivative compound of ginkgolide B, has been recently isolated from the leaves of Ginkgo biloba. It is a powerful natural platelet activate factor (PAF) antagonist, and also has obvious protect effects for cerebral ischemia. However, no reports have been described for the pharmacokinetic study of GK. In this study, a simple, sensitive and reliable ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method has been developed for the determination of GK in rat plasma and tissues. Biological samples were pretreated by an efficient liquid-liquid extraction with ethyl acetate. The chromatographic separation was achieved on an Agilent ZORBAX SB-Aq column (4.6 mm × 50 mm, 1.8 μm) with a mobile phase of 0.5% aqueous formic acid (A)-menthol (B). Quantitation was carried out on a triple quadruple mass spectrometry using positive electrospray ionization in multiple reaction monitoring mode. Diazepam was used as internal standard (IS). The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively. The developed method was fully validated and successfully applied to the pharmacokinetics and tissue distribution study of GK after intravenous administration. The current results have indicated that pharmacokinetic parameters of GK vary in a dose-dependent manner with rapid elimination in 4h. The major distribution tissues of GK in rats were liver and kidney. This study would provide critical information to promote the future study of GK.

show abstract

Plasma pharmacokinetics and tissue distribution study of physalin D in rats by ultra-pressure liquid chromatography with tandem mass spectrometry

Cited by 12 publications

References 15 publications

Identification and quantitative analysis of physalin D and its metabolites in rat urine and feces by liquid chromatography with triple quadrupole time‐of‐flight mass spectrometry

Identification and quantitative analysis of physalin D and its metabolites in rat urine and feces by liquid chromatography with triple quadrupole time‐of‐flight mass spectrometry

In vivo pharmacokinetics of and tissue distribution study of physalin B after intravenous administration in rats by liquid chromatography with tandem mass spectrometry

Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry

Contact Info

Product

Resources

About